medigraphic.com
Instituto Nacional de Salud Pública

2011, Number 5

<< Back Next >>

salud publica mex 2011; 53 (5)

Carcinogenesis

Martín CMT, Civetta JD

Language: Spanish
References: 52
Page: 405-414
PDF size: 205.15 Kb.


ABSTRACT

Cell division is controlled by stimulatory and inhibitory systems. The origin of cancer is monoclonal, and in order that a normal cell switches its phenotype and becomes a neoplastic cell, genetic mutations must occur on it. These genetic mutations modify the products that in normal conditions the gene would codify and, finally, cause cancer. Cancer may be hereditary (due to mutations in one or both of germinal cells alleles) or sporadic (due to action of environmental mutagenic agents). The mechanisms that may cause alterations on genes may be genetic or epigenetic. Genetic mechanisms occur when structural alterations of genome are present and the epigenetic processes occur due to enzymatic alterations or alterations on its substrates. Carcinogenesis has three stages: initiation, promotion and progression. The last of these stages, progression, is exclusive of malignant transformation and implies the capacity to invade surrounding or distant tissues. For metastasis to take place, many mechanisms are required: angiogenesis, matrix degradation, cell migration, evasion of host immune response and metastatic colonization. This article presents a partial review of current bibliography about concepts related to carcinogenesis and conveys the minimum necessary information to achieve an understanding of this complex process.


REFERENCES

  1. Blanco J, Bullón M. Cuadernos de genética. España: Marban, 1987.

  2. Cavenee WK, White RL. The genetic basis of cancer. Sci Am 1995;272(3):72-79.

  3. Estevez R. Oncología Clínica. El Salvador: Edic. Univ., 1978.

  4. Celada A. Factores de transcripción y control de la expresión génica. Investig Cienc 1991;179:42-52.

  5. Bergers E, van Diest PJ, Baak JP. Cell cycle analysis of 932 flow cytometric DNA histograms of fresh frozen breast carcinoma material. Correlations between flow cytometric, clinical, and pathologic variables. MMMCP Collaborative Group. Multicenter Morphometric Mammary Carcinoma Project Collaborative Group. Cancer 1996 1;77(11):2258-2266.

  6. Moreno S. Comienzo de mitosis. Investig Cienc, 1992;187:62-70

  7. Radman, Wagner R. Fidelidad de la duplicación del ADN. Investig Cienc 1988;145:20-30.

  8. Arango MC, Llanes L, Díaz T, Faxas ME. La apoptosis: sus características y su papel en la transformación maligna de la célula. Rev Cubana Oncol 1997;13(2):126-134.

  9. Weinberg RA. The molecular basis of oncogenes and tumor suppressor genes. Ann N Y Acad Sci 1995;758:331-338.

  10. Cohen SM, Ellwein LB. Genetic errors, cell proliferation, and carcinogenesis. Cancer Res 1991;51(24):6493-6505.

  11. Michelin S. El oncogén c-erbB2 (neu/Her-2) y su expresión en el cáncer de mama humano. Revista Latinoamericana de Mastología1997;1(3):181-190

  12. Laird PW. Oncogenic mechanisms mediated by DNA methylation. Mol Med Today 1997;3(5):223-229.

  13. Margulies EH, Cooper GM, Asimenos G, Thomas DJ, Dewey CN, Siepel A, et al. Analyses of deep mammalian sequence alignments and constraint predictions for 1% of the human genome. Genome Res 2007;17(6):760-774.

  14. Perry ME, Levine AJ. Tumor-suppressor p53 and the cell cycle. Curr Opin Genet Dev 1993;3(1):50-54.

  15. Cramer DW, Muto MG, Reichardt JK, Xu H, Welch WR, Valles B, et al. Characteristics of women with a family history of ovarian cancer. I. Galactose consumption and metabolism. Cancer 1994;74(4):1309-1317.

  16. Romero MP. Cáncer y Metástasis, relación con radicales libres. Oncología1993;3(3):79-94.

  17. Narod SA. Hereditary Breast Carcinoma Syndromes. Workshop on Heritable Cancer Syndromes and Genetic Testing. Supplement to Cancer 1997;537-541.

  18. Gallo R. Virus oncogénicos ARN. Seminarios de Oncología 126-148. Buenos Aires: Editorial Médica Panamericana, 1977.

  19. Green M. Virus ADN: replicación, expresión del gene tumoral y papel en el cáncer humano. Seminarios de Oncología 103-125. Editorial Médica Panamericana. Buenos Aires, 1977.

  20. Iwasawa A, Nieminen P, Lehtinen M, Paavonen J. Human papillomavirus DNA in uterine cervix squamous cell carcinoma and adenocarcinoma detected by polymerase chain reaction. Cancer 1996;77(11):2275-2279.

  21. Wolf CR. Metabolic factors in cancer susceptibility. Cancer Surv 1990;9(3):437-474.

  22. León J, Guerrero I, Pellicer A. Activación de los oncogenes por radiación y agentes químicos. Investig Cienc 1988;143:20-34.

  23. Liu ET. Genomic technologies and the interrogation of the transcriptome. Mech Ageing Dev 2005;126(1):153-159.

  24. Rhodes DR, Yu J, Shanker K, Deshpande N, Varambally R, Ghosh D, et al. Large-scale meta-analysis of cancer microarray data identifies common transcriptional profiles of neoplastic transformation and progression. Proc Natl Acad Sci USA 2004;101(25):9309-9314.

  25. Jensen ON. Modification-specific proteomics: characterization of posttranslational modifications by mass spectrometry. Curr Opin Chem Biol 2004;8(1):33-41.

  26. Pastwa E, Somiari SB, Czyz M, Somiari RI. Proteomics in human cancer research. Proteomics Clin Appl. 2007;1(1):4-17.

  27. Greider CW. Telómeros, telomerasa y cáncer. Investig Cienc 1996; 20-26.

  28. Blackburn EH. Structure and function of telomeres. Nature 1991;350(6319):569-573.

  29. Feng J, Funk WD, Wang SS, Weinrich SL, Avilion AA, Chiu CP, et al. The RNA component of human telomerase. Science 1995;269(5228):1236-1241.

  30. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PL, et al. Specific association of human telomerase activity with immortal cells and cancer. Science 1994;266(5193):2011-2015.

  31. Perez M, Dubner D, Michelín S, Gisone P, Carosella E. Telómeros y reparación de daño genómico: Su implicancia en patología humana. Medicina (B. Aires) 2002;62(6):593-603.

  32. Li S, Crothers J, Haqq CM, Blackburn EH. Cellular and gene expression responses involved in the rapid growth inhibition of human cancer cells by RNA interference-mediated depletion of telomerase RNA. J Biol Chem 2005;280(25):23709-23717.

  33. Maschioveccho V. Telomerasa: nuevo marcador tumoral. Departamento Inmunología y Genética. Buenos Aires: Inmunología IACA, 2007.

  34. Li S, Blackburn EH. Expression and suppression of human telomerase RNA. Cold Spring Harb Symp Quant Biol 2006;71:211-215.

  35. Redon R, Ishikawa S, Fitch KR, Feuk L, Perry GH, Andrews TD, et al. Global variation in copy number in the human genome. Nature 2006;444(7118):444-454.

  36. Wong KK, deLeeuw RJ, Dosanjh NS, Kimm LR, Cheng Z, Horsman DE, et al. A comprehensive analysis of common copy-number variations in the human genome. Am J Hum Genet 2007;80(1):91-104.

  37. Maino R. Proteómica. El desafío de la post-genómica, Med.Interna, 2007.

  38. Teramoto N, Sarker AB, Tonoyama Y, Yoshino T, Hayashi K, Takahashi K, et al. Epstein-Barr virus infection in the neoplastic and nonneoplastic cells of lymphoid malignancies. Cancer 1996;77(11):2339-2347.

  39. Colville-Nash PR, Willoughby DA. Growth factors in angiogenesis: current interest and therapeutic potential. Mol Med Today 1997;3(1):14-23.

  40. Toi M, Kondo S, Suzuki H, Yamamoto Y, Inada K, Imazawa T, et al. Quantitative analysis of vascular endothelial growth factor in primary breast cancer. Cancer 1996;77(6):1101-1106.

  41. Maciag T. Mecanismos moleculares y celulares de la angiogénesis. En: De Vita V, ed. Avances en Oncología. España: Espaxs Publicaciones Médicas, 1990:109-127.

  42. Liotta L. Factores de motilidad autocrina tumoral. En: De Vita V, ed. Avances en Oncología. España: Espaxs Publicaciones Médicas, 1988:33-49.

  43. Halachmi S, Marden E, Martin G, MacKay H, Abbondanza C, Brown M. Estrogen receptor-associated proteins: possible mediators of hormoneinduced transcription. Science 1994;264(5164):1455-1458.

  44. Khan SA, Rogers MA, Obando JA, Tamsen A. Estrogen receptor expression of benign breast epithelium and its association with breast cancer. Cancer Res 1994;54(4):993-997.

  45. Liotta L. Invasión de las células cancerosas y metástasis. Investig Cienc 1992;187:24-48.

  46. Urterger A. Los componentes de la matriz extracelular como blanco de terapias antimetastásicas. Nuevas Tendencias en Oncología 1997;6 (4):273-279

  47. Sheu J, Shih Ie M. HLA-G and immune evasion in cancer cells. J Formos Med Assoc 2010;109(4):248-257.

  48. Old J. El factor de necrosis tumoral. Investig Cienc 142 1988; 20-28.

  49. Rosemberg S, et al. Linfocitos infiltrantes del tumor. En: De Vita V, ed. Avances en Oncología. España: Espaxs Publicaciones Médicas, 1990:37-63.

  50. Rosemberg S. Inmunoterapia del cáncer. Investig Cienc 1990;166:26-42.

  51. Carosella ED, Moreau P, Le Maoult J, Le Discorde M, Dausset J, Rouas-Freiss N. HLA-G molecules: from maternal-fetal tolerance to tissue acceptance. Adv Immunol 2003;81:199-252.

  52. Habergger A. Alelos de HLA clase I y II implicados en la susceptibilidad y resistencia a la infección por HIV y en la progresión del SIDA (tesis). Universidad de Buenos Aires Argentina 2005;33-47.




2020     |     www.medigraphic.com